Skip to main
  1. Stocks
  2. Ideaya Biosciences Inc
  3. Forecast
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is viewed favorably because its lead darovasertib program is now at a major inflection point, with the NDA submitted in 3Q26 under the RTOR program and clinical data supporting a potentially broad label across HLA-A2 positive and negative metastatic uveal melanoma. The company also has multiple late-stage shots on goal, including IDE849 with encouraging efficacy and survival signals in SCLC and NEC and planned 3Q trials, plus IDE892 and IDE397 advancing through MTAP-deleted and RAS-combination strategies that could unlock sizable long-term sales potential. Financially, IDEAYA ended 3Q26 with $1.15B in cash and equivalents and guided runway into 2030, while higher R&D and SG&A reflect deliberate investment in a pipeline that appears increasingly de-risked and commercially relevant.

Bears say

IDEAYA Biosciences is viewed as highly exposed to binary clinical outcomes, with the downside case hinging on darovasertib failing to gain approval in MUM or neo-adjuvant UM and on the company not establishing clear forward paths for its pipeline. Disappointing PFS data for daro, a challenged neo-adjuvant UM market, and possible efficacy or safety setbacks for IDE397 or IDE849 could severely impair the investment case, while commercialization remains uncertain. With multiple layers of clinical, regulatory, liquidity, competitive, and partnership risk, the shares could trade closer to cash at $10/share if these programs underperform.

IDYA has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

IDYA Analyst Forecast & Price Prediction

Get the latest IDYA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IDYA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 11 analysts, IDYA has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


IDYA Analyst Forecast & Price Prediction

Get the latest IDYA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IDYA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IDYA stock data and trends